US Patent

US8168218 — Delayed release tablet with defined core geometry

Method of Use · Assigned to Jagotec AG · Expires 2028-01-07 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a press-coated tablet with a core containing a drug substance, designed to release the substance with a lag time of 2-6 hours.

USPTO Abstract

A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.

Drugs covered by this patent

Deltasone (prednisone) · Generic (originally Schering)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1269`	—	Deltasone

Patent Metadata

Patent number: US8168218
Jurisdiction: US
Classification: Method of Use
Expires: 2028-01-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Jagotec AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.